After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene (CELG) or Gilead (GILD) .

Cramer addressed these stocks on Thursday's edition of CNBC's Mad Money.

Meanwhile, President Trump is set to deliver a speech on drug pricing on Friday. 

For exclusive investing insight from Jim Cramer, get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!